- PR Newswire•27 days ago
ENGLEWOOD, Colo., March 28, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced that it entered into a Waiver and Consent Letter Agreement with CVI Investments, Inc., amending the terms of warrants previously issued to CVI on September 1, 2016. Under the Waiver and Consent Agreement, CVI waived the right to have its warrant exercise price reduced, and the number of Ampio shares of Common Stock underlying the warrant increased in the event the Company secures any financing, including debt, which includes issuing or selling shares of Common Stock for a price per share less than the warrant exercise price. CVI also waived the prohibition on Ampio's ability to issue or sell shares of its Common Stock, options or convertible securities at a price which varies or may vary with the market price of the Common Stock or pursuant to an equity credit line or similar "at-the-market" type offering.
- American City Business Journals•last month
In a recent 10-K filing with the Securities and Exchange Commission, Douglas County-based Ampio (AMPE) said "a 'going concern' opinion could impair our ability to finance our operations through the sale of debt or equity securities or through bank financing. Ampio is developing Ampion, an anti-inflammatory drug designed to treat to severe pain associated with osteoarthritis of the knee , which company officials are excited about. In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion, both from a regulatory perspective as well as commercial," said Michael Macaluso, chairman, and CEO, in a statement .
- PR Newswire•last month
Ampio Updates Intellectual Property and Regulatory Exclusivity Strategy to Support the Commercialization of Ampion™
ENGLEWOOD, Colo., March 23, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the issuance of China Patent No 102210852 B for the production of an active ingredient of Ampion™, which completes the intellectual property protection in China. Mr. Macaluso, Ampio's CEO, noted that "With the issuance of this patent, the Company's two-prong strategy to obtain comprehensive and overlapping Intellectual Property and Regulatory Exclusivity protection for a commercial launch of Ampion™, expected in 2018, is nearing completion.
AMPE : Summary for Ampio Pharmaceuticals, Inc. - Yahoo Finance
Ampio Pharmaceuticals, Inc. (AMPE)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.54 - 0.61|
|52 Week Range||0.52 - 4.32|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.59|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|